Board of Directors

Mr. Stein Holst Annexstad Chair

Mr. Annexstad holds a BA in Commerce from the Norwegian School of Economics (1969).
He has senior industry experience, both at executive and Board levels.
He is former executive of Dyno Industrier AS (fine chemicals), and became the CEO of the pharmaceutical firm Nycomed AS (subsequently merged with Amersham Plc and thereafter merged with GE). He was head of AS Isco Group, an Executive Search and Corporate Advisory Group. Mr. Annexstad was in 1996 a co-founder of NorgesInvestor AS, an Oslo-based Private Equity firm, and was in 2008 the first Chairman of Investinor AS (the VC of the Norwegian State). At the same time he was Chairman of Algeta ASA, the pharmaceutical startup that successfully developed Xofigo (prostate cancer drug) and was aquired by Bayer Health Care in 2014. Other previous Chairman positions comprise commercial banking, business school, public R&D and various industrial enterprises.

Mrs. Hilde Furberg Non-Executive Director

Hilde Furberg has over 30 years of commercial experience in Pharma and Biotech, she is currently Senior Vice President Rare Diseases EMEA at Genzyme a Sanofi Company. Previously her roles were Vice President and General Manager of Nordic Benelux and Nordic General Manager at Genzyme. Prior to joining Genzyme, Ms. Furberg was Managing Director and part-owner of Pharmalink and held a number of roles at Baxter including Managing Director Sweden. She is currently a board member at Pharmalink and has held board positions at Algeta, Clavis, Pronova and Probi.

Dr. Susan Foden Non-Executive Director

Dr. Susan Foden holds a number of Non-Executive Directorships with both public and private companies and public funding bodies in the biotechnology and healthcare field, including Vectura plc., Source Bioscience plc., Rainbow Seed Fund, Cascade Ltd and Oxford Ancestors Ltd. Previously Dr Foden held positions in venture capital and UK biotechnology companies. From 2000 to 2003 she was an Investor Director with the London-based VC firm Merlin Biosciences Limited, and was CEO of the technology transfer company Cancer Research Campaign Technology. She studied biochemistry at the University of Oxford from where she obtained an MA and a DPhil.

Mrs. Kari Grønås Non-Executive Director

Kari Grønås (M. Sc. Pharm) has more than 25 years of experience in drug development and the commercialisation of new products including securing regulatory approvals. She has significant management experience including leadership of cross functional and governance teams.
She was SVP Operations at Algeta ASA, and has had leading positions in both Photocure ASA and Nycomed/Amersharm Health. She holds a non-executive directorship at Lytix Biopharma AS, is Chairman of the Board of the Norwegian Pharmaceutical Society, and is currently working as a consultant within biotech.

Dr. Stener Kvinnsland Non-Executive Director

Dr. Stener Kvinnsland has more than 30 years of experience in oncology. He is Chair of Board, Oslo University Hospital. Among Dr. Kvinnsland’s previous roles, he was Chief Executive Officer of the Bergen Hospital Trust (Helse Bergen), Head of the Department of Oncology and Medical Physics at Haukeland University Hospital, Professor of Medicine (Oncology) at the University of Bergen and Director Clinical R&D, Oncology for Pharmacia & Upjohn in Milan.

Mr. Sveinung Hole Non-Executive Director

Sveinung Hole is the CEO of Bergen Research Foundation and the Kristian Gerhard Jebsen Foundation. Hole holds a number of Board positions amongst others at Sarsia Seed AS, Norwegian Venture Capital Association, Prophylix Pharma AS and VoluSense AS. Formerly he was the CEO of the investment fund Sarsia Seed AS, Board Member of Bergen Hospital Trust (Helse Bergen) and Director of Anesthesia and Intensive Care at Haukeland University Hospital. Hole has also held various top management positions (Market, Strategy, Internet) at Telenor Corporation and been Regional Managing Director/Director of Global Strategies at the Berlitz Corporation. Hole holds a Master of International Management from BI Norwegian Business School.

Mr. Jon Øyvind Eriksen Non-Executive Director

Jon Øyvind Eriksen is an Investment Director at Investinor AS, a Norwegian government funded venture capital company. He is currently Non-Executive Director at Boostcom Group, Novelda and Signicat. He holds an MSc in Biotechnology from the Norwegian University of Science and Technology (NTNU), and a graduate degree in Russian and German from the University of Bergen. He has been awarded an MBA with Distinction from London Business School, and is a CFA Charterholder.